In Oct 2007, the FDA introduced that the labeling for all PDE5 inhibitors, including tadalafil, needs a much more prominent warning from the potential possibility of unexpected hearing decline as the results of write-up-marketing and advertising stories of non permanent deafness connected to use of PDE5 inhibitors.[19]Not often, additional severe U